Brief: Bone Biologics Extends Rhnell-1 Shelf Life To 24 Months
Brief: Bone Biologics CEO Issues Letter To Stockholders Highlighting Company Update And Outlook
Bone Biologics Corp expected to post a loss of 53 cents a share - Earnings Preview
Bone Biologics Corp expected to post a loss of 58 cents a share - Earnings Preview
Brief: Bone Biologics Announces Closing Of $5 Million Public Offering
Brief: Bone Biologics Announces Pricing of $5.0 Million Public Offering
Brief: Bone Biologics Files Patent Application For Bone Regeneration Technology
Brief: Bone Biologics Regains Compliance With Nasdaq Continued Listing Requirements
Brief: Bone Biologics Files For Mixed Shelf Of Up To $35 Million – SEC Filing
Brief: Bone Biologics Announces 1-For-6 Reverse Stock Split
Bone Biologics Corp reports results for the quarter ended March 31 - Earnings Summary
Bone Biologics Corp reports results for the quarter ended September 30 - Earnings Summary
Brief: Bone Biologics Appoints Phillip T. Meikle To Its Board Of Directors
Bone Biologics Corp reports results for the quarter ended in June - Earnings Summary
Bone Biologics Corp reports results for the quarter ended in March - Earnings Summary
Brief: Bone Biologics And Jeffrey Frelick Entered Into An Amended And Restated Letter Agreement On March 12
Brief: Bone Biologics Announces Closing Of $2 Million Public Offering
Brief: Bone Biologics Reports Progress With NB1 Clinical Program
Brief: Bone Biologics Regains Compliance With Nasdaq Continued Listing Requirements